Peter Bullard, Senior Vice President of Manufacturing at NovaCina, recently shared insights into the Australian CDMO’s unique position in the global pharmaceutical market. Speaking to PharmaSource at CPHI Milan he explains how despite being only 18 months old, NovaCina boasts
Speaking at CPHI Milan, Craig Cox, Vice President of Global Sales, Bioprocessing at Ecolab, shared insights into the company’s role in supporting drug development and manufacturing. “Ecolab supports drug development within the process, including chromatography resins for biologic purification and
SpectronRx, based in Indianapolis, is expanding its operations by establishing a new radiolabeling facility in Belgium. The company announced a binding agreement to build the plant at the Belgian Nuclear Research Center (SCK CEN) in Mol. The construction is expected
Cambrex, a global contract development and manufacturing organisation (CDMO), has announced the opening of a new cGMP stability storage facility in Durham, North Carolina. The facility, operated by its subsidiary Q1 Scientific, expands the company’s capability to provide temperature-controlled storage
SMC Ltd., a medical device contract manufacturer, has announced a significant expansion of its facility in Devens, Massachusetts. The 160,000 sq. ft. extension will introduce three new ISO 8 cleanrooms and a cold chain storage warehouse maintained at 2-8 degrees
OmniaBio Inc., a contract development and manufacturing organisation (CDMO) specialising in cell and gene therapy (CGT), has announced the opening of its new manufacturing and AI centre of excellence in Hamilton, Ontario. The facility is now the largest of its
eXmoor Pharma, a contract development and manufacturing organisation (CDMO) specialising in cell and gene therapy (CGT), has partnered with Virica Biotech in a project aimed at improving the manufacture of adeno-associated vectors (AAVs), a vital component of gene therapies. Funded
Mabion’s position as a cost-effective, high-quality CDMO in Central Europe offers an attractive option for North American biotechs looking to optimise their manufacturing strategies.
AGC Biologics announced that the U.S. Food and Drug Administration (FDA) approved three Biologics License Applications (BLAs) from a March 2024 inspection at its Seattle facility. The inspection, which covered three commercial biologics, resulted in the approval of two FC-fusion
Cellular Origins and Fresenius Kabi have signed a development agreement to integrate Fresenius Kabi’s cell therapy processing technologies into Cellular Origins’ robotic manufacturing platform, Constellation. This collaboration is expected to enhance manufacturing efficiency for cell and gene therapies (CGTs), helping
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
